K
Knut Helmke
Researcher at University of Hamburg
Publications - 11
Citations - 3586
Knut Helmke is an academic researcher from University of Hamburg. The author has contributed to research in topics: Medicine & Sarcoma. The author has an hindex of 8, co-authored 8 publications receiving 3111 citations.
Papers
More filters
Journal ArticleDOI
Prognostic Factors in High-Grade Osteosarcoma of the Extremities or Trunk: An Analysis of 1,702 Patients Treated on Neoadjuvant Cooperative Osteosarcoma Study Group Protocols
Stefan S. Bielack,Beate Kempf-Bielack,Günter Delling,G. Ulrich Exner,Silke Flege,Knut Helmke,Rainer Kotz,Mechthild Salzer-Kuntschik,M. Werner,Winfried Winkelmann,Andreas Zoubek,Heribert Jürgens,Kurt Winkler +12 more
TL;DR: Axial tumor site, male sex, and a long history of symptoms were associated with poor response to chemotherapy in univariate and multivariate analysis.
Journal ArticleDOI
Osteosarcoma Relapse After Combined Modality Therapy: An Analysis of Unselected Patients in the Cooperative Osteosarcoma Study Group (COSS)
Beate Kempf-Bielack,Stefan S. Bielack,Heribert Jürgens,Detlev Branscheid,Wolfgang E. Berdel,G. Ulrich Exner,Ulrich Göbel,Knut Helmke,Gernot Jundt,Hartmut Kabisch,Mathias Kevric,Thomas Klingebiel,Rainer Kotz,Rainer Maas,Rudolf Schwarz,Michael Semik,Jörn Treuner,Andreas Zoubek,Kurt Winkler +18 more
TL;DR: Time to relapse and tumor burden correlate with postrelapse outcome in osteosarcoma and Chemotherapy, particularly chemotherapy with more than one agent, may contribute to limited improvements in outcome.
Journal ArticleDOI
Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label, international, randomised controlled trial
Neyssa Marina,Sigbjørn Smeland,Stefan S. Bielack,Mark L. Bernstein,Gordana Jovic,Mark Krailo,Jane Hook,Jane Hook,Carola A.S. Arndt,Henk van den Berg,Bernadette Brennan,Bénédicte Brichard,Kenneth L.B. Brown,Trude Butterfass-Bahloul,Gabriele Calaminus,Heike E. Daldrup-Link,Mikael Eriksson,Mark C. Gebhardt,Hans Gelderblom,Joachim Gerss,Robert E. Goldsby,Allen M. Goorin,Richard Gorlick,Holcombe E. Grier,Juliet Hale,Kirsten Sundby Hall,Jendrik Hardes,Douglas S. Hawkins,Knut Helmke,Pancras C.W. Hogendoorn,Michael S. Isakoff,Katherine A. Janeway,Heribert Jürgens,Leo Kager,Thomas Kühne,Ching C. Lau,Patrick J. Leavey,Stephen L. Lessnick,Leo Mascarenhas,Paul A. Meyers,Hubert Mottl,Michaela Nathrath,Zsuzsanna Papai,R. Lor Randall,Peter Reichardt,Marleen Renard,Akmal Safwat,Cindy L. Schwartz,Michael C. Stevens,Sandra J. Strauss,Lisa A. Teot,Mathias Werner,Matthew R. Sydes,Jeremy Whelan +53 more
TL;DR: The EURAMOS-1 results do not support the addition of ifosfamide and etoposide in patients with poorly responding osteosarcoma, and the primary outcome measure was event-free survival measured in the intention-to-treat population.
Journal ArticleDOI
Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial
Stefan S. Bielack,Sigbjørn Smeland,Jeremy Whelan,Neyssa Marina,Gordana Jovic,Jane Hook,Mark Krailo,Mark C. Gebhardt,Zsuzsanna Papai,James O. Meyer,Helen Nadel,R. Lor Randall,Claudia Deffenbaugh,Rajaram Nagarajan,Bernadette Brennan,G. Douglas Letson,Lisa A. Teot,Allen M. Goorin,Daniel Baumhoer,Leo Kager,Mathias Werner,Ching C. Lau,Kirsten Sundby Hall,Hans Gelderblom,Paul A. Meyers,Richard Gorlick,Reinhard Windhager,Knut Helmke,Mikael Eriksson,Peter M. Hoogerbrugge,Paula J. Schomberg,Per-Ulf Tunn,Thomas Kühne,Heribert Jürgens,Henk van den Berg,Tom Böhling,Susan Picton,Marleen Renard,Peter Reichardt,Joachim Gerss,Trude Butterfass-Bahloul,Carol D. Morris,Pancras C.W. Hogendoorn,Beatrice Seddon,Gabriele Calaminus,Maria Michelagnoli,Catharina Dhooge,Matthew R. Sydes,Mark L. Bernstein +48 more
TL;DR: Investigation of maintenance therapy with pegylated interferon alfa-2b in patients whose osteosarcoma showed good histologic response (good response) to induction chemotherapy found that MAP plus IFN-α-2B was not statistically different from MAP alone.
Journal ArticleDOI
Tumor size and prognosis in aggressively treated osteosarcoma.
P. Bieling,N. Rehan,Peter Winkler,Knut Helmke,Rainer Maas,N. Fuchs,Stefan S. Bielack,U. Heise,Heribert Jürgens,Jörn Treuner,R. Romanowski,U. Exner,Rainer Kotz,K. Winkler +13 more
TL;DR: Initial tumor size is an important and easily obtainable prognostic factor in osteosarcoma and may serve as a basis for risk-adapted therapy and is best represented by the absolute three-dimensional measure ATV.